C
INKT icon

Covestor’s MiNK Therapeutics INKT Stock Holding History

Covestor’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
119
-12
-9% -$134 ﹤0.01% 2060
2025
Q4 		$1K Hold
131
– – ﹤0.01% 2081
2025
Q3 		$2K Hold
131
– – ﹤0.01% 1953
2025
Q2 		$1K Buy
131
+27
+26% +$203 ﹤0.01% 2016
2025
Q1 		$1K Sell
104
-1
-1% -$9 ﹤0.01% 2006
2024
Q4 		$1K Hold
105
– – ﹤0.01% 2058
2024
Q3 		$1K Sell
105
-1
-0.9% -$8 ﹤0.01% 2006
2024
Q2 		$1K Hold
106
– – ﹤0.01% 2024
2024
Q1 		$1K Sell
106
-1
-0.9% -$9 ﹤0.01% 2001
2023
Q4 		$1K Sell
107
-1
-0.9% -$10 ﹤0.01% 1986
2023
Q3 		$1K Buy
108
+50
+86% +$814 ﹤0.01% 1951
2023
Q2 		$1K Buy
+58
New +$1.16K ﹤0.01% 1962

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Covestor's INKT Position: Q1 2026 in Review

Covestor reduced its MiNK Therapeutics (INKT) stake by 9.2% in Q1 2026, selling an estimated $134 and leaving 119 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Covestor first reported a position in INKT in Q2 2023 and has held it in 12 quarters since. The position peaked at $2K in Q3 2025. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Covestor held 119 shares of MiNK Therapeutics worth $1K as of Q1 2026.
  • Covestor sold 12 MiNK Therapeutics shares in Q1 2026, an estimated $134.
  • MiNK Therapeutics made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2060 holding.
  • Covestor first reported a position in MiNK Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Covestor's MiNK Therapeutics position peaked at $2K in Q3 2025.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.